A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery. DEXBASU study - Trial 2017-001454-33
Access comprehensive clinical trial information for 2017-001454-33 through Pure Global AI's free database. This phase not specified trial is sponsored by Dr. Albert Lecube Torello and is currently Ongoing. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2017-001454-33
Ongoing
Trial Details
EU Clinical Trials Register • 2017-001454-33
A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery. DEXBASU study
Study Focus
Sponsor & Location
Dr. Albert Lecube Torello
Astra Zeneca
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1 Known type-1 diabetes or LADA diabetes
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
EU Clinical Trials Register
2017-001454-33
Non-Device Trial